ERX1000

ERX1000 is a first-in-class, orally administered small molecule leptin sensitizer in development for the treatment of obesity and related diseases. It is designed to enhance the body's response to endogenous leptin, a hormone critical for regulating appetite and metabolism. By improving leptin sensitivity, ERX1000 aims to address one of the key mechanisms underlying obesity—leptin resistance. The drug is being developed by ERX Pharmaceuticals and has completed Phase 1 clinical trials demonstrating proof-of-concept in obese subjects; it is currently undergoing Phase 2 clinical evaluation in the United States[1][2][3][4][5][6]. The mechanism of action involves modulation of central pathways that regulate hunger and weight loss, based on research into how brain systems communicate metabolic signals[6].